Europe Prostate Cancer Diagnostics Market report is the broad market research report which studies the challenges, market structures, opportunities, driving forces, emerging trends, and competitive landscape of Healthcare industry. Moreover, the report revises general market conditions, estimates market share and possible sales volume of Healthcare industry, figure out the probable market for a new product to be launched and discover the most appropriate method for the distribution of certain product. By taking into consideration specific base year and historic year, calculations in the report have been performed which interprets the market performance in the forecast years by giving information about what the market definition, classifications, applications, and engagements are.
All the data and information collected in the winning Europe Prostate Cancer Diagnostics Market report for research and analysis is represented in the form of graphs, charts or tables for the sensible understanding of users. The market report is a truthful source of information which offers a telescopic view of the current market trends, situations, opportunities and status. Furthermore, big sample sizes have been utilized for the data collection in this report which suits the necessities of small, medium as well as large size of businesses. This market analysis report works on all the aspects of market that are required to create the finest and top-notch Europe Prostate Cancer Diagnostics Market research report.
Prostate cancer diagnostics market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 12.5% in the forecast period of 2021 to 2028 and is expected to reach USD 1,604.78 million by 2028 from USD 636.30 million in 2020. Increasing focus on the disease burden and increasing awareness regarding the disease are the major drivers which are propelling the market in the forecast period.
Download Sample PDF of Europe Prostate Cancer Diagnostics Market: - https://www.databridgemarketresearch.com/request-a-sample/?dbmr=europe-prostate-cancer-diagnostics-market
The major companies providing prostate cancer diagnostics are F. Hoffmann-La Roche Ltd, Siemens Healthcare GmbH, OPKO Health Inc., Abott, Beckman Coulter, Inc. (A Subsidiary of Danaher), among others domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Europe Prostate Cancer Diagnostics Market Scope and Market Size
The prostate cancer diagnostics market is categorized into eight notable segments which are based on the product type, diagnostics type, age group, type, stage, sample type, end users and distribution channel.
· On the basis of product type, the prostate cancer diagnostics market is segmented into instruments, reagents & consumables and accessories. In 2021, reagents & consumables segment is dominating in the prostate cancer diagnostics market as it includes the PSA testing products which is the primary test recommended for preliminary testing. PSA measures protein made by cells in prostate gland which is the first line of diagnosis for prostate cancer.
· On the basis of diagnostics type, the prostate cancer diagnostics market is segmented into preliminary screening tests and confirmatory tests. In 2021, preliminary screening tests segment is dominating in the prostate cancer diagnostics market as the number of preliminary tests surpass the number of confirmatory tests by significant percentage.
· On the basis of age group, the prostate cancer diagnostics market is segmented into adult, pediatric and geriatrics. In 2021, geriatrics segment is dominating in the prostate cancer diagnostics market as around 60% of cases are diagnosed in men over 65 year of age. The average age of prostate cancer diagnostics is 66 years. The disease rarely occurs in those younger than 40. The number of new cases diagnosed in black men is 60% higher than to the number of new cases diagnosed in white men.
· On the basis of type, the prostate cancer diagnostics market is segmented into prostatic adenocarcinoma, small cell carcinoma and others. In 2021, prostatic adenocarcinoma segment dominates the prostate cancer diagnostics market because more than 95 percent of prostate cancers are adenocarcinomas which develop in the gland cells and line of the prostate gland. Nearly, all the men with prostate cancer have this type. It is the second leading cause of cancer-related death in men. Once the cancer reaches a certain stage, then the abnormal cells spread to other parts of the body, hence causing metastasis which leads to dominating the segment of the market.
· On the basis of stage, the prostate cancer diagnostics market is segmented into localized prostate cancer, recurrent/advanced prostate cancer and castration-resistant prostate cancer (metastatic and non-metastatic). In 2021, localized prostate cancer segment dominates the prostate cancer diagnostics market as approximately 80 percent to 85 percent of all prostate cancers are detected in the local or regional stages which represent stages I, II and III. Most of the men diagnosed and treated at the local or regional stages will be disease-free after five years. This type of cancer does not spread in any of the nearby tissues or to distant parts of the body. The stages present in localized prostate cancer are stage 1 and 2. The growth of tumor in low-risk localized prostate cancer is slow.
· On the basis of sample type, the prostate cancer diagnostics market is segmented into blood, tissue, urine and others. In 2021, blood segment is dominating the prostate cancer diagnostics market as blood is the primary sample for the most common preliminary test that is PSA test and due to easy availability of blood, less complex procedure of blood sample collection doesn’t take much time which is expected to dominate the prostate cancer diagnostics market.
· On the basis of end user, the prostate cancer diagnostics market is segmented into independent diagnostic laboratories, hospitals, cancer research institutes, clinics, ambulatory surgical centers and others. In 2021, Independent diagnostic laboratories segment is dominating the prostate cancer diagnostics market as this segment is specialized in conducting various prostate cancer diagnostics. Moreover, independent diagnostic laboratories enable the facilitation of robust, on-time, cost-effective and high quality diagnostic care and services in safe healthcare environment and are convenient for consulting physician/healthcare institution to outsource bulk diagnostics tests to independent diagnostic laboratories for better customer services.
· On the basis of distribution type, the prostate cancer diagnostics market is segmented into direct tender and retail sales. In 2021, direct tender segment dominates the prostate cancer diagnostics market as they are the primary source of procurement of reagents, consumables, devices and accessories by healthcare organizations and diagnostic labs. With the increasing cost of healthcare, healthcare service providers are focusing on better services for customers along with reducing the overall cost. The procurement of products through direct tender is highly cost effective for healthcare providers.
Browse a Detailed Summary of the Europe Prostate Cancer Diagnostics Market Research Report @ https://www.databridgemarketresearch.com/reports/europe-prostate-cancer-diagnostics-market
How Does the Report Aid Your Business Discretion?
• This section of this Market report highlights some of the most relevant factors and growth enablers that collectively ensure a high-end growth spurt
• The report unravels details on pronounced share assessments across both country-wise as well as region-based segments
• A leading synopsis of market share analysis of dynamic players inclusive of high-end industry veterans
• New player entry analysis and the scope of new business models
• The report includes strategic recommendations for new business veterans as well as established players seeking novel growth avenues
• A detailed consultation service based on historical as well as current timelines to ensure feasible forecast predictions
• A thorough evaluation and detailed study of various segments as well as sub-segments across regional and country-specific developments
• Details on market estimations, market size, dimensions
• A review of market competitors, their high-end product and service portfolios, dynamic trends, as well as technological advances that portray high-end growth in this Market
Browse More Reports
https://www.databridgemarketresearch.com/reports/global-prostate-cancer-diagnostics-market
https://www.databridgemarketresearch.com/reports/asia-pacific-prostate-cancer-diagnostics-market
https://www.databridgemarketresearch.com/reports/north-america-prostate-cancer-diagnostics-market
About Data Bridge Market Research, Private Ltd
Data Bridge Market Research Pvt Ltd is a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability level and advanced approaches. We are committed to uncover the best consumer prospects and to foster useful knowledge for your company to succeed in the market.
Data Bridge Market Research is a result of sheer wisdom and practice that was conceived and built-in Pune in the year 2015. The company came into existence from the healthcare department with far fewer employees intending to cover the whole market while providing the best class analysis. Later, the company widened its departments, as well as expands their reach by opening a new office in Gurugram location in the year 2018, where a team of highly qualified personnel joins hands for the growth of the company. “Even in the tough times of COVID-19 where the Virus slowed down everything around the world, the dedicated Team of Data Bridge Market Research worked round the clock to provide quality and support to our client base, which also tells about the excellence in our sleeve.”
Contact:
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek